This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jay A. Levy, MD
University of California School of Medicine San Francisco

JAMA. 1996;276(15):1219-1220.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—The response by Drs Kinloch-de-Loës and colleagues to my Controversies reiterates the difficulty in knowing whether surrogate markers give a true insight into a clinical benefit. I maintain my premise that drug therapy should mimic the natural cellular immune responses associated with low viral RNA to control HIV and sustain a longterm asymptomatic course. Kinloch-de-Loës et al emphasized neutralizing antibodies, but these most likely have no effect on a clinical course: the cellular immune response is the major component in preventing progression to disease. My emphasis has been on approaches to increase this cellular immune activity, which can control HIV by a variety of mechanisms, particularly suppression of virus replication.¹ This comment, however, does not negate the conclusion by Kinloch-de-Loës et al (with which I agree) that a treatment regimen needs to be judged by its clinical effectiveness, not by any particular measure, although the reason for the effectiveness . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?